About Prevtec Microbia

Prevtec Microbia is a Canadian biotechnology company specialized in the development of vaccines and other technologies that help fight against bacterial diseases in food animals. In a world where antibiotic use in animal production is increasingly controlled, we develop innovative alternatives to antibiotics. Our products represent sustainable solutions. Prevtec Microbia is an innovation-centric company that operates in many areas of the world through strategic alliances, particularly in Canada and Europe. Prevtec Microbia is proud to be part of the quest for better ways to feed the world.
Born Global Video
(english only)
$33 billion

Estimated value of the global animal health industry by 2020*

* Vetnosis


Number of countries where Coliprotec® F4 is approved for use


We have been devising innovative solutions to challenges in livestock production for over a decade.


Coliprotec® F4/F18 is launched in the EU through Elanco: Prevtec Microbia delivers a million doses


Prevtec Microbia Inc. (“Prevtec”) is pleased to provide an update on the commercial launch of its bivalent vaccine Coliprotec® F4/F18 in the European Union, a front line product against post weaning diarrhea (PWD) in pigs. Prevtec’s distribution partner Elanco, the animal health division of Eli Lilly, launched Coliprotec® F4/F18 on May 4th at the 9th European Symposium of Porcine health Management (ESPHM) in Prague. The…

Read more

Market Authorization granted to Prevtec Microbia for Coliprotec® F4/F18 in Canada


Prevtec Microbia is pleased to announce that it has been granted a market authorization by the Canadian Food Inspection Agency’s Canadian Centre for Veterinary Biologics (CFIA-CCVB) to commercialize its Coliprotec® F4/F18 vaccine. Coliprotec® F4/F18 is an oral live bacterial vaccine for the active immunization of piglets of at least 18 days of age against Post-Weaning Diarrhea caused by F4-positive and F18-positive enterotoxigenic and edema disease…

Read more

    Antimicrobial resistance (AMR) is resistance of a microorganism to an antimicrobial medicine to which it was originally sensitive. AMR occurs naturally but the phenomenon is hugely increased by excessive and inappropriate use of antimicrobial medicines and poor infection control practices in animals and humans.



    Source: European Commission, http://europa.eu/rapid/press-release_STATEMENT-15-6097_en.htm